SCPH | scPharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.27 - 3.50
52 Week Range	3.08 - 6.71
Beta	0.27
Implied Volatility	121.80%
IV Rank	36.92%
Day's Volume	306,943
Average Volume	350,244
Shares Outstanding	50,040,100
Market Cap	168,134,736
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-11-17

Valuation
Profitability
Growth
Health
P/E Ratio	-1.72
Forward P/E Ratio	N/A
EPS	-1.95
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	135
Country	USA
Website	SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

SCPH's peers: BYSI, DMAC, HROW, IKT, MIST, MNPR, ONCY, PRTA, MCRB, LIFE, LYRA, CNTA, SCPS, KTTA, IOVA, XCUR

*Chart delayed

Analyzing fundamentals for SCPH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see SCPH Fundamentals page.

Watching at SCPH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SCPH Technicals page.